The success of treatment for @entity2132 ( @entity2132 ) remains disappointing. The immunomodulatory ability of bone marrow (BM)-derived mesenchymal stem cells (MSCs) shows promise in treating GVHD, especially given its previous success in treating @entity1 with acute GVHD (aGVHD). The potential efficacy and safety issues for treating cGVHD, particularly @entity2132 , remain to be clarified, however. Here, we report 4 @entity1 with @entity2132 who received MSCs expanded ex vivo from unrelated donors by intra-BM injection. After MSC infusion, the ratio of helper T lymphocyte (Th) 1 cells to Th2 cells was dramatically reversed, with an increase in @entity1198 and a decrease in Th2 achieving a new balance. Correspondingly, symptoms gradually improved in all 4 @entity1 . During the course of MSC treatment, the @entity1 ' vital signs and laboratory results remained normal. At the time of this report, none of the 4 @entity1 had experienced recurrence of @entity1778 . Although this study alone cannot guarantee the application of MSCs in @entity2132 , our findings strongly suggest that this treatment is therapeutically practicable, with no detectable side effects. This approach may provide new insight into the clinical treatment of @entity2132 , with the aim of greatly increasing the survival rate in @entity1 with @entity1778 who undergo allogeneic BM transplantation (BMT).

Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of XXXX : clinical report.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['sclerodermatous chronic graft-versus-host disease', 'ScGVHD'] @entity1198 :: ('51497', 'Gene') :: ['Th1']
@entity2132 :: (MESH:D006086,Disease) :: ['sclerodermatous chronic graft-versus-host disease']
